Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...

Top stocks for 2025 are from the companies that have proven growth track records and strong outlooks, with more potential ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...